SCHEMBL3016067

SCHEMBL3016067

COc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
LMNA P02545 4/20 0.51
MAPK1 P28482 2/20 0.51
TSHR P16473 1/20 0.51
MAPT P10636 3/20 0.49
USP2 O75604 1/20 0.49
RECQL P46063 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TP53 P04637 1/20 0.46
POLB P06746 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PIK3CD O00329 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CG P48736 1/20 0.44
PTPN11 Q06124 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018680 0.93 MAPT (0.49) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3015962 0.92 MAPT (0.52) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3003684 0.92 LMNA (0.47) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3001708 0.91 TDP1 (0.47) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3018692 0.91 ALDH1A1 (0.48) ALDH1A1LMNATSHRPOLBSMN1; SMN2
SCHEMBL3016050 0.90 ALDH1A1 (0.46) ALDH1A1LMNATSHRPIK3CAKMT2A
SCHEMBL3015788 0.90 MEN1 (0.46) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3015084 0.89 TSHR (0.48) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3017125 0.89 MAPT (0.55) ALDH1A1LMNAMAPK1TSHRMAPT
SCHEMBL3014551 0.89 MAPT (0.49) ALDH1A1LMNAMAPK1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885LMNA 80/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.